Our boards

David Ormesher provides leadership and direction for closerlook, inc., a digital marketing agency serving the pharmaceutical industry. As founder and former CEO, Ormesher has grown it into a recognized leader in creating innovative relationship marketing solutions that help pharmaceutical brands build and maintain meaningful relationships with their most valuable healthcare professionals.

Since founding the company in 1987, David has created a rich, cohesive culture at closerlook by maintaining a hands-on approach to building client success and sustaining lasting account relationships. He has guided the growth and evolution of the firm, attracting a world-class team of account, strategy, user experience, design, technology, data analytics and relationship-marketing services experts. David is a frequent speaker at marketing conferences and a recognized thought leader in the areas of interactive and relationship marketing for the pharmaceutical industry.

This past year, David was named to the board of the Lurie Children’s Hospital Foundation and to the Innovation Board of the XPRIZE Foundation. He serves on the boards of the Lyric Opera of Chicago; i.c.stars, an innovative business and leadership training program for inner city youth; and is a founder of Bigger Future, a social-enterprise building the capacity of high-potential entrepreneurs in Rwanda. He is also an adjunct professor at the Illinois Institute of Technology Stuart School of Business where he teaches customer relationship management.

Laura Ferris Anderson, Chairperson on the Revieve Board of Advisors, has served as Chief of Staff to the Office of the Midwest Chairman for JPMorgan Chase. She managed the strategic planning and initiative implementation for the region’s senior leadership across multiple business lines and staff functions. She had served as a Senior Banker in J.P. Morgan’s private banking business, managing relationships and banking needs for a wide variety of clients, including corporate executives and business owners. Previously, Laura served as a Director of Payments Strategy, eCommerce, and of a major image enabled transformation of check processing. She also has experience in consulting and government affairs.

An active civic leader, Anderson serves on the Executive Committees of the Board of Directors of the Chicagoland Entrepreneurial Center and of the Wood Family Foundation. She serves on the Board of Directors of the IL Mentoring Partnership and the Advisory Board of Best Buddies Illinois as well as the Women’s Boards of the Field Museum and the Joffrey Ballet.

She is a member of the Alumni Board of Governors of Georgetown University, where she earned a Bachelor of Science, a Master of Public Policy and a Master of Business Administration. A native of Massachusetts, Anderson lives in Chicago with her husband, Matt, and their daughter, Ellen.

Jeff Aronin is a bioscience entrepreneur who built and has sold several successful biotech companies. He has earned a record number of novel drug approvals that improve the lives of patients. Jeff is known for innovating, developing and commercializing scientific discoveries in areas of high need, such as neurology.

In 2017, Jeff founded Paragon Biosciences, where he is chairman and chief executive officer. Paragon is among the life sciences industry’s most successful company creators, investing billions with its partners to build companies that improve patient lives through advanced biotechnology. Through Paragon, Jeff launched multiple companies including Harmony Biosciences (NASDAQ: HRMY), Emalex Biosciences and CiRC Biosciences, with several others in development.

Throughout his career, Jeff identified scientific innovations with the highest potential to change lives, building a series of businesses that successfully developed laboratory discoveries into high-impact therapeutics and technologies. The research and development teams at Jeff’s companies are responsible for 50 novel drug approvals.

Jeff has received numerous honors for entrepreneurship and his contributions to life sciences, including the EY Entrepreneur of the Year award, induction into the Chicago Entrepreneur Hall of Fame and most recently, the TITAN Entrepreneur of the Year award.

Outside of his businesses, Jeff devotes time to civic and philanthropic endeavors. He is the founder and chairman of MATTER, a health technology incubator offering philanthropic support for life sciences entrepreneurs. Jeff currently serves on several corporate and civic boards including Discover Financial Services, The Aspen Institute and the Weizmann Institute of Science. He is a frequent lecturer at the University of Chicago’s Booth School of Business and Northwestern University’s Kellogg School of Business.

Laurie is a co-founder of Cooley’s Chicago office and the co-head of the Chicago corporate group. Her practice focuses on the representation of emerging and growth-stage companies and the investors who support them. She advises clients on a wide range of venture-backed private financings and counsels companies at all stages of growth on day-to-day corporate matters. In addition to her robust emerging companies and venture capital practice, Laurie’s experience includes advising public and private companies on mergers and acquisitions, securities offerings, U.S. Securities and Exchange Commission reporting and compliance and governance matters.   Laurie, who is heavily engaged in Chicago’s vibrant startup ecosystem and entrepreneurial community, serves on the boards of directors of non-profits 1871, a business incubator supporting technology and other startups in the Chicago area, and of MATTER, a Chicago-based healthcare startup incubator, community nexus and corporate innovation accelerator. She has lectured on a variety of topics relating to venture financings, including at Northwestern Pritzker School of Law, University of Michigan Law School and 1871.   Laurie has been recognized in Crain’s Chicago’s “Who’s Who” list in 2023 and 2024.

Andrew is an experienced healthcare executive and serial entrepreneur with a successful track record of identifying, founding, and building healthcare businesses from concept to commercialization to acquisition by Fortune Global 1000 firms. These include founding two successful diagnostic imaging companies, and leading both through acquisitions by Siemens and Olympus. His leadership experience also includes acting as startup CEO of critical care company which was acquired by Medtronic. He has managed manufacturing and quality systems implementation, execution of multi-center clinical trials, and regulatory clearances for new technologies in Europe and the US. Mr. Cittadine received his BA, BS, and MS from Stanford and an MBA from Northwestern’s Kellogg School of Management.

Steven Collens is CEO of MATTER, the premier healthcare incubator and innovation hub. MATTER helps healthcare innovators achieve their goals faster and more efficiently and increases the odds of their success. MATTER has incubated more than 1,000 healthcare technology ventures and helps leading health systems, life sciences companies, payers and foundations activate innovation to advance their goals.

Prior to assuming his current role, Steven was senior vice president at Pritzker Group, the investment firm led by Tony and J.B. Pritzker. In that capacity, he led the team that created 1871, Chicago’s center for digital startups, which became the top-ranked business incubator in the world in 2018. He previously worked at Abbott in a variety of domestic and international functions, including product management, policy and public affairs. Prior to Abbott, Steven served as legislative assistant to U.S. Senator Carol Moseley-Braun.

Steven holds an MBA from Northwestern University’s Kellogg School of Management and a BA from Washington University in St. Louis. He chairs the board of Hubbard Street Dance Chicago and serves on the boards of 1871 and the Chicago High School for the Arts. He is a member of ChicagoNEXT, the Chicago mayor’s council on technology and innovation, a Leadership Greater Chicago fellow, and a member of the Economic Club of Chicago and the Commercial Club of Chicago.

Bill Dixon has over 45 years of business experience across diverse industries, including professional services, healthcare providers and payors, nonprofits, business services, engineering, financial services, construction, biotechnology, medical devices and transportation. His subject matter expertise is in corporate governance, leadership, executive compensation and human capital management.

Throughout his career, Bill has demonstrated expertise in corporate governance, not-for-profit taxation, business systems and analytics, organizational change and business strategy execution.

Beyond his professional work, Bill advocates for changing healthcare, humanitarian causes, economic empowerment and youth education. His interests include arts, culture, national/global affairs and community development. He is active in professional associations like the National Association of Corporate Directors, the Private Directors Association, WorldatWork and the American Heart Association.

Joel Farran is an executive and organizational advisor, consultant and coach focused on helping individuals and organizations grow and renew in equitable and sustainable ways.

Joel is part of Ad Lucem Group — helping organizations and individuals achieve peak performance — where he specializes in strategy, communications and community investments/partnerships for healthcare leaders and nonprofit organizations.

Leveraging a 20-year career in healthcare, Joel previously served as chief brand officer and senior VP at Health Care Service Corporation (HCSC) — the largest not-for-profit health insurer in the country. His broad experience at HCSC included corporate and business unit strategy development, mergers and acquisitions, large-scale initiative implementation, analytics governance, sales support and marketing and overseeing corporate relations and community impact functions.

In addition to being a board member at MATTER, Joel has served as a board member for the Good Foot Catalyst and is emeritus chair and vice chair of the Arts and Business Council of Chicago. Joel was also among the business and community leaders on the community and culture team of The Commercial Club of Chicago, which helped shape the formation of P33 — focused on elevating Chicago to a tier one technology and innovation hub promoting inclusive economic growth.

Joel is passionate about inclusive growth, innovation and accessibility across traditional healthcare organizations, civic and community spaces. He earned his M.S. in Health Systems Management from Rush University Medical Center College of Health Sciences and a B.S. in Psychology from University of Illinois Champaign-Urbana. In his spare time, he enjoys creative writing and is a senior instructor with Master S.H. Yu Martial Arts — achieving formal recognitions as a 3rd Dan Black Belt from the In Nae Ryu Martial Arts International Headquarters and Kukkiwon Tae Kwon Do World Headquarters.

For the past two years, Steven A. Gould led Chicago Innovation Mentors (CIM), which supports university-based and local new technology innovation ventures through the use of mentor teams. MATTER acquired CIM in January 2016. Steven has extensive and broad-based experience in both clinical and scientific research in an academic environment, and executive management throughout the entire life cycle of an entrepreneurial biotechnology company.

Steven is also the founder and principal of The Gould Consulting Group LLC, which provides advisory services to companies and universities seeking to develop and capitalize on biotechnology and life science innovations, and to venture investors evaluating promising and potentially transforming companies working in areas of disruptive science. Steven was previously a scientific founder, chairman and CEO of Northfield Laboratories Inc., a publicly traded biotechnology company that was focused on developing a hemoglobin-based oxygen carrier as a blood substitute. Prior to Northfield he was chief of surgery at Michael Reese Hospital and Medical Center and professor of surgery at the University of Chicago and then the University of Illinois at Chicago.

He has dealt with the full spectrum of issues related to financing startup companies from the initial venture investment through multiple subsequent rounds, the initial public offering and follow-on offerings, and the wide range of challenges in the development of new and innovative therapies. Steven received his BA from Williams College and his MD from Boston University School of Medicine. He completed his residency training in surgery at Yale and the University of Vermont, and a research fellowship at Michael Reese and the University of Chicago.

Steve Hamman is a senior-level healthcare executive, advisor and investor with 30+ years proven experience in growing and leading a large health plan organization. He has extensive experience managing a multi-billion dollar P&L with consumer-focused service operations as well as advising private equity and venture capital companies focused on operational due diligence, market assessment, payer relations and value-based strategy.

Steve is the immediate past president of Blue Cross Blue Shield of Illinois, where he was responsible for the state’s largest health insurer with almost nine million members, $22 billion in revenue and over $40 billion in medical spend. His responsibilities included overall business and financial performance, long-term growth strategy, sales, care management, network/provider contracting, government relations and communications across all commercial lines of business, Medicare and Medicaid.

Steve served in a variety of management roles within Health Care Service Corporation (HCSC) during his tenure with the company — which operates Blue Cross and Blue Shield Plans in Illinois, Montana, New Mexico, Oklahoma and Texas. Prior to assuming the president role, he served as senior vice president, enterprise network and provider partnerships, where he was responsible for HCSC’s network and provider partnership strategy and investments, provider and network analytics, alternative payment model development, and affordability of care across HCSC’s five markets.

Steve holds a bachelor’s degree in economics and mathematics from Colorado College and a master’s in business administration in information systems from the Quinlan School of Business at Loyola University in Chicago. He currently serves on the boards of Special Olympics Illinois, MATTER and New City Church while also actively participating on the healthcare advisory boards for Madison Dearborn Partners, Forge Health, Stellar Health, Carium Health, Rezilient Health, CertifyOS and as an executive in residence for MATTER.

Dr. Jeffrey Kent brings to Sling over two decades of life sciences experience in clinical development, medical affairs and medical/commercial strategy, including rare diseases, and expertise in multiple product launches including CELEBREX, HUMIRA, KRYSTEXXA, and TEPEZZA. Most recently he served as Executive Vice President, Medical Affairs and Outcomes Research at Horizon Therapeutics. Dr. Kent has had the opportunity to support multiple New Drug Applications, Biologics License Applications, U.S. Food & Drug Administration Advisory Committee Meetings, and product launches around the world.

Dr. Kent earned a BA in economics from Franklin and Marshall College and his Doctor of Medicine from Jefferson Medical College.

James L. Madara, MD, serves as the CEO and executive vice president of the American Medical Association (AMA), the nation’s largest physician organization. He holds the academic title of adjunct professor of pathology at Northwestern University.

Since taking the reins of the AMA in 2011, Dr. Madara has helped sculpt the organization’s visionary long-term strategic plan. As an extension of this vision, he now also serves as chairman of Health2047 Inc., an independent, design-driven innovation firm based in San Francisco whose mission is to help advance the AMA’s goal of improving the health of the nation.

Prior to arriving at the AMA, Dr. Madara spent the first 22 years of his career at Harvard Medical School, receiving both clinical and research training, serving as a tenured professor and as director of the NIH-sponsored Harvard Digestive Diseases Center. Following five years as chair of pathology at Emory, Dr. Madara served as dean of the medical school and CEO of the hospitals at the University of Chicago, bringing together the university’s biomedical research, teaching and clinical activities. While there, he oversaw the renewal of the institution’s biomedical campus and engineered significant new affiliations with community hospitals, teaching hospital systems, community clinics and national research organizations.

Dr. Madara also served as senior advisor with Leavitt Partners, an innovative healthcare consulting and private-equity firm founded by former Secretary of Health and Human Services, Mike Leavitt. Having published more than 200 original papers and chapters, Dr. Madara has received both national and international awards, and served as editor-in-chief of the American Journal of Pathology and as president of the American Board of Pathology.

In addition to Modern Healthcare consistently naming him as one of the nation’s 50 most influential physician executives, as well as one of the nation’s 100 most influential people in healthcare, he is a past recipient of a prestigious MERIT Award from the National Institutes of Health. He received the 2011 Davenport Award for lifetime achievement in gastrointestinal disease from the American Physiological Society and the 2011 Mentoring Award for lifetime achievement from the American Gastroenterological Society. Dr. Madara is an elected member of both the American Society of Clinical Investigation and the Association of American Physicians. He also co-chairs the Value Incentives and Systems Innovation Collaborative of the National Academy of Medicine (NAM), and is a member of NAM’s Leadership Consortium for Value & Science-Driven Healthcare.

Dr. Madara and his wife Vicki have 2 children, Max and Alexis.

Dr. Suzet McKinney, a nationally recognized public health expert, serves as principal and director of life sciences at Sterling Bay. In her role, Dr. McKinney leads the strategy to expand Sterling Bay’s footprint in life sciences nationwide, pursue grant programs for laboratory incubation and graduation space and advance the work of various Sterling Bay life sciences initiatives including Prysm Institute.

Prior to joining Sterling Bay, Dr. McKinney was CEO and executive director of the Illinois Medical District (IMD) where she managed medical research facilities, labs, a biotech business incubator, universities, four hospitals and more than 40 healthcare-related facilities. Before IMD, Dr. McKinney served as deputy commissioner for the Bureau of Public Health Preparedness and Emergency Response at Chicago Department of Health.

Dr. McKinney holds her doctorate degree from the University of Illinois at Chicago School of Public Health. She earned her master’s degree from Benedictine University, and her bachelor’s degree from Brandeis University. She holds faculty appointments at Harvard’s T.H. Chan School of Public Health and the UIC School of Public Health.

Pete McNerney has over 30 years of healthcare operating and venture capital experience. In addition to co-founding Thomas, McNerney & Partners, Pete co-founded Coral Ventures in 1992, where he was responsible for healthcare investing. Pete has served on the board of a number of the Coral Ventures’ and Thomas, McNerney and Partners’ portfolio companies. Prior to joining Coral in 1992, Pete was a co-founder and managing partner of The Kensington Group, a firm specializing in providing management services to early stage companies in the healthcare field. In 1986, he founded and served as CEO of Memtec North America, a company established to commercialize cross flow membrane microfiltration technology in North America. Previously, Pete spent 11 years with Baxter Healthcare Corporation, where he held various general management positions in the U.S., Europe, Middle East and Southeast Asia. He has served as president of the Minnesota Venture Capital Association and is on the board of trustees of Blue Cross and Blue Shield of Minnesota. A Certified Public Accountant, Pete received a B.A. from Yale and an M.B.A. from Stanford University. Pete was a 2014 fellow at Harvard’s Advanced Leadership Initiative program.

Ellen Rudnick currently serves as a senior advisor on entrepreneurship and adjunct professor at Chicago Booth. She previously served as executive director of the Polsky Center and Clinical Professor of Entrepreneurship and, together with Steve Kaplan, was instrumental in the creation of the entrepreneurship programming at Chicago Booth. Prior to joining the Chicago Booth faculty, Ellen spent 25 years in business management and entrepreneurial activities, primarily in the healthcare and health information services industries. During this time, she was president and CEO of Healthcare Knowledge Resources, president of HCIA, chairman of Pacific Biometrics and corporate vice president of Baxter Healthcare Corporation.

She works with the many startups that emerge from Chicago Booth’s entrepreneurship programs. Both her governance activities and startup interests help her to bridge the gap in the classroom between the theoretical and the real world.

Ellen has been the recipient of a number of honors, including Today’s Chicago Woman 20th Anniversary Hall of Fame, the YWCA Leadership Award, the Illinois Venture Capital Richard J. Daley award and the 1871 Entrepreneurial Champion award. She serves or has served on numerous corporate boards including Liberty Mutual, First Midwest Bank, HMS Holdings, Patterson Companies, Oxford Health Plans, Northshore University Healthcare Research and Development, the Chicagoland Entrepreneurial Center,1871 and MATTER.

Ellen earned her bachelor’s degree from Vassar College and an MBA from Chicago Booth.

Edrice Simmons is the vice president, US oncology, solid tumors at Abbvie. She is a proven commercial leader and talent magnet, who brings her passion for building the long term commercial strategy for the first of its kind solid tumor business unit at AbbVie.

Previously, Edrice Simmons was the senior vice president, USbrands – Allergan Aesthetics. In this role, Edrice was responsible for overseeing the U.S. brand commercial strategy for facial aesthetics (BOTOX® cosmetic and Juvéderm® filler franchise), plastic surgery & regenerative medicine, body contouring and SkinMedica products with a focus on maximizing the value of the brands.

Prior to her senior level role at Allergan Aesthetics, Edrice was responsible for leading the immunology therapeutic pipeline and asset strategy at AbbVie, where she was responsible for building the immunology pipeline strategy. Additionally, Edrice oversaw the commercial development of immunology pipeline assets (Skyrizi and RinVoq) from discovery through phase III, leading the new product development immunology team to drive the early commercial strategy and oversaw business development opportunities closing a large deal within her first year.

Edrice joined AbbVie in 2014 as senior marketing director, gastroenterology and advanced to vice president, US gastroenterology where she was responsible for growing the blockbuster product, Humira from $1B in revenue to $6B in just 4 short years. Prior to joining Abbvie, Edrice worked at Eli Lilly & Company for 16 years. While there, she served in various roles in both sales and marketing spanning across US and global roles leading blockbuster brands across therapeutic areas (oncology, endocrinology, women’s/men’s health and neuroscience).

Edrice is passionate about her work with the Healthcare Business Women’s Association, the National MBA Association and other local community organizations. She has served on the board of directors of four non-profit organizations and is a member of Delta Sigma Theta Sorority, Incorporated.

Edrice earned a bachelor’s degree in clinical/medical social work from Ball State University and an MBA in marketing from Indiana Wesleyan University.

As president, Brian Snell is responsible for the overall financial performance, long-term growth strategy and strategic planning of the state’s largest health insurance company.

Brian leads Illinois Sales and Account Management, focused on delivering customer-first operational excellence. He also leads the teams that lead the Plan’s operations and delivery, care management, provider relations and community engagement initiatives.

Brian is an accomplished leader with more than 30 years of experience with BCBSIL, having previously served in underwriting, account management and sales roles. Brian serves on the Board of the Pathway to Adventure Council (PTAC), the nation’s foremost youth program for character development and values-based leadership training to more than 15,000 youth in the Chicagoland and Northwest Indiana area. He also serves on the Board of Directors for Dearborn National and the Illinois Manufacturing Association (IMA). Brian holds a Bachelor of Arts degree from the University of Illinois and an MBA from DePaul University.

Jim Sullivan, PhD is co-founder and CEO of Vanqua. In addition, he has been a Venture Partner with Orbimed since January 2019. Previously, he was the Vice President of Research at Abbvie where he was responsible for the company’s research efforts in a variety of therapeutic/disease areas including oncology, immunology, neurology, hepatitis C and cystic fibrosis. Jim has advanced more than 100 compounds into clinical development across a number of disease states and technology platforms.

These include products on the market for HCV (Mavyret and Viekira), the first-in-class Bcl2 selective inhibitor, Venclexta, for hematological cancers, a new oral agent for patients with rheumatoid arthritis, RINVOQ, and multiple compounds currently in Phase II or III clinical trials. He has authored/co-authored more than 130 scientific publications and is an inventor on 11 patents. Jim is an adjunct faculty member at Northwestern University and serves on the board of several companies and foundations including Regis Technologies, Genomics Medicine Ireland, Genuity Science, MATTER Healthcare Incubator, Chicago Biotechnology Accelerator and the Pistoia Alliance. He earned his bachelor’s degree and Ph.D. in biochemistry from Trinity College Dublin and conducted post-doctoral research in neurobiology at Northwestern University.

Nancy Sullivan built Illinois Ventures’ team of top-tier investment and operations professionals and leads them in managing fundraising, investment strategy and limited partner relationships. She has deep experience in commercialization and entrepreneurship, specifically in the biotech and therapeutics industries.

A key advisor to startups, Nancy assists companies in obtaining venture capital funding, recruiting management teams and advising on business development and commercialization matters. She serves on the board of Diagnostic Photonics.

Prior to taking the helm at Illinois Ventures, Nancy served as the director of the Office of Technology Management at the University of Illinois at Chicago, and as senior director of strategic planning and business development for a biotechnology startup.

A Chicago native, Nancy is an active member of the Illinois healthcare and tech communities. She serves on the boards of iBio, a life sciences industry association that represents the 85,000 life sciences employees at member companies, universities, service providers and venture firm; Cures Within Reach, a research nonprofit that brings stakeholders together to undertake repurposing research opportunities; and MATTER a Chicago-based health tech accelerator. Nancy is also a German Marshall Fellow and participated in Leadership Greater Chicago.

Phil is currently the Chief Commercial Officer at Precigen, a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in areas such as immuno-oncology, autoimmune disorders and infective diseases.

For over 30 years prior to his move to Biotech, Phil worked for several notable ‘big pharma’ companies (Merck, Sharp & Dohme, AstraZeneca, Bristol-Myers Squibb and Astellas) in global, regional and domestic commercial roles of increasing seniority across the UK, Europe, Japan, Australia and the U.S.

His recent career has been heavily focused on Oncology, initially driving commercial success with the first of the new wave of Immuno-Oncology agents (Yervoy), and subsequently orchestrating growth/ launches across multiple solid and hematological cancers across the globe. Phil’s most recent big pharma role was Senior Vice President and Head of the $3 billion U.S. Oncology Business Unit at Astellas Pharma, where he successfully steered the business through a period of exceptional launch activity and transformative growth across prostate, urothelial and gastric cancers as well as Acute Myeloid Leukemia.

He has been a Board Member for the Illinois Biotechnology Innovation Organization (iBIO) and is a current Board Member for the global life sciences start-up incubator, MATTER. In addition, he served as a core member of the Joint Steering Committees for two successful alliances: with Seagen/Pfizer for Padcev and with Pfizer for Xtandi.

Glen Tullman is the chief executive officer of Transcarent, the first comprehensive, consumer-directed health and care platform for employees of self-insured employers and their families. Born in Silicon Valley, Transcarent’s platform empowers consumers with the kind of information, guidance and access that leads to better care, better outcomes and more cost-effective decisions for everyone.

Glen is the former executive chairman, chief executive officer and founder of Livongo Health, the first at-scale consumer digital health company to truly empower people with chronic conditions to live better and healthier lives using data science.

In his final year, he led Livongo through the largest consumer digital health Initial Public Offering in history, a secondary offering, a convertible debt offering that raised over $550 million, and the industry’s largest merger to date between Livongo and Teladoc Health, valuing Livongo at $18.5 billion and beginning a new era of consumer centric virtual care.

A visionary leader and entrepreneur, Glen previously ran two other public companies that changed the way health care is delivered. During his time as chief executive officer of Allscripts, the company was the leading provider of electronic prescribing, practice management, and electronic health records. Glen led Allscripts IPO and secondary offerings. Prior to Allscripts, he was ehief Executive officer of Enterprise Systems, the leading resource management systems for hospitals, which he also took public and then sold to McKesson/HBOC. Before entering healthcare, Glen served as president and COO of CCC Information Systems, a provider of computerized systems for the property and casualty insurance sector.

Glen is also one of two founding partners at 7wireVentures, one of the highest returning venture capital funds in Illinois. He is the author of On Our Terms: Empowering the New Health Consumer, in which he proposes new solutions to address the chronic-condition epidemic facing our country.

Glen is dedicated to finding a cure for diabetes and other chronic conditions—and to keeping people healthy until cures are found. A strong proponent of philanthropy, he was honored in 2019 with a Robert F. Kennedy Human Rights Ripple of Hope Award for his career focused on improving the safety, empathy and efficiency of our healthcare system. He also serves as a chancellor to the International Board of the Juvenile Diabetes Research Foundation and as a board member and the incoming chairperson of the American Diabetes Association. Glen has three amazing children that inspire him every day.

Dr. Eric E. Whitaker is physician-investor who is chairman of several companies including TWG Partners, LLC. He and his partner co-founded Symphonix Health Holdings, LLC and grew it to over 430,000 clients in 48 states over a three-year premium period. They sold Symphonix in January 2016 and investors made 15 times their money with an IRR of 280.

Until March 2012, Dr. Whitaker was the executive vice president, strategic affiliations and associate dean of community-based research at the University of Chicago Medical Center. He was also an operating advisor for Nautic Partners, a middle market private equity fund, and sat on the boards of two of its portfolio companies. He holds Series 7 and 63 licenses as well as being licensed for medicine in the State of Illinois.

Dr. Whitaker served as director of the Illinois Department of Public Health until October 2007. In this capacity, Dr. Whitaker oversaw an agency with a budget of $450 million with over 1,200 employees statewide, as well as three laboratories and seven regional offices.

In 1991, Dr. Whitaker represented the 30,000 members of the American Medical Student Association as its national president while testifying twice before the U.S. Congress regarding national health insurance and minority health issues. In November 2003, he was named as one of Crain’s Chicago Business’ Forty under Forty Chicago’s rising stars in business and government.

Dr. Whitaker received his undergraduate degree in chemistry from Grinnell College in 1987. In 1993 he received his master’s degree in public health from the Harvard School of Public Health and a medical degree from the University of Chicago Pritzker School of Medicine. He also has completed coursework at the Northwestern Kellogg Graduate School of Management. Dr. Whitaker serves on the boards of Grinnell College, the DuSable Museum of African American History and the Chicago Council on Global Affairs. He formerly served on the boards of the Chicago Symphony Orchestra, Chicago Public Media and the Economic Club of Chicago.

As the leader of CareQuest Innovation Partners, the for-profit arm of the world’s largest oral health non-profit (CareQuest Institute for Oral Health), Katie advances the mission of improving oral health for all through identifying, validating and scaling innovation and integration across the health ecosystem.

She accomplishes this through impact investing, board advisory, programs including CareQuest’s SMILE Health accelerator and piloting new programs and solutions with mission-aligned partners to derive critical proof points to catalyze change.

Formerly a leader of Deloitte Consulting’s healthcare practice, she has over a decade of experience partnering with large health plans, health systems and emerging health players including retail, consumer products, technology and startup companies to design, pilot and scale innovative solutions for millions of consumers.

She brings a global perspective and network from her experience in Israel, Australia, India and Korea, building operations, partnerships and AI & data capabilities. She is a frequent author and speaker on the future of health, oral health innovation, global ecosystems, women+ health and business model strategy.

Katie holds an MBA from the University of Chicago Booth and a Bachelor of Science in Finance from the University of Illinois Champaign-Urbana. She is deeply involved in the Chicagoland community, including engagement with local incubators, universities and the Juvenile Diabetes Research Foundation for over 20 years.

Marco is an independent senior healthcare innovation transformer with over 20 years of experience in medical device and digital health, leading global teams across R&D, Global Customer Insights, Portfolio Strategy, Growth Acceleration and Open Innovation through strategic customer-, business- and cultural transformations.

Currently, Marco is the founder and principal of Transform83, a strategy consulting firm focused on guiding, coaching and mentoring corporate leaders, innovation units and startups in their endeavor to accelerate value creation for customers, the business and investors.

In his recent role as Global Head Customer Insights & Growth Acceleration, Marco led the development of Roche’s strategic customer insights foundation and created growth strategies for the business units. In addition, Marco led the development and implementation of Roche’s corporate & startup accelerator program from the ground up, resulting in the company’s business model pipeline.

Marco has been a startup mentor and Executive in Residence at MATTER Health for over 6 years, guiding startup’s challenging journeys to prove they can create value for patients, providers and investors.

Marco holds an Executive MBA from Quantic School of Business & Technology, a Bachelor’s Degree in Mechanical Engineering, a Bachelor’s Degree in Polymer Engineering from the University of Applied Science in Bern and Northwestern Switzerland.

Tom Kawalec is a managing director in Accenture’s life sciences practice, bringing over 27 years of consulting experience including the management of Accenture’s global relationships with some of the world’s largest life sciences companies. Tom specializes in creating effective customer-centric operating models and digital capabilities for large-scale business-to-business companies within life sciences and healthcare, with prior experience in the travel, consumer goods and telecommunications industries.

As the Midwest life sciences practice lead, Tom has P&L responsibility for Accenture’s clients within this geography. In this role, Tom is also part of Accenture’s global life sciences leadership team, setting strategy and priorities and nurturing the 15,000+ global life science practitioners.

Tom holds a BS in aerospace and mechanical engineering from the Illinois Institute of Technology and an executive MBA program certificate from the Kellogg School of Management at Northwestern University.

Christopher (Chris) Leggett is the Senior Director and Head of Market Transformation in the Pain Business Unit of Vertex Pharmaceuticals.

Chris has extensive industry experience in marketing, public policy, market access and healthcare innovation. Prior to joining Vertex, Chris was the Lead for Global Commercial Innovation at Genmab. He was responsible for identifying and implementing differentiated capabilities to enhance provider and patient experience. Chris also previously led the Immunology Market Access Marketing team at Janssen and established the Commercial Innovation function at Novo Nordisk, Inc. Chris earned a BA in Political Science and MBA from Loyola University Maryland.

Nadine has more than three decades of experience in the pharmaceutical industry focused on business operations and commercialization of therapies. She has worked across multiple therapeutic areas, with a significant focus on neurological and psychiatric conditions.

Nadine currently serves as executive director, business operations at Lundbeck Pharmaceuticals. In this role, Nadine manages day-to-day operations for Lundbeck US as well as strategic projects focused on commercial capabilities development, business growth and change management.

Nadine joined Lundbeck in 2009 and has held various roles throughout the company focused on developing and improving business operations. Her initial role focused on integrating the U.S. business within its global parent following a pivotal acquisition. From there, Nadine was integral in establishing business operations and developing organizational capabilities for Lundbeck’s psychiatry franchise during a time of significant growth and portfolio expansion in the U.S. As the company grew, Nadine’s remit expanded to support the operational development of Lundbeck’s neurology franchise. Her current role and responsibility spans all business operations for Lundbeck US.

Prior to joining Lundbeck, Nadine served as director of marketing and director of medical affairs at Abbott. She began her career at Eli Lilly and Company where she held a variety of marketing and sales positions over 14 years. Nadine also spent 10 years in retail pharmacy working closely with patients.

Nadine holds a B.S. in pharmacy from Purdue University and a master’s in business administration from the University of Michigan.

Joe Maliekal has served as AbbVie’s commercial innovation lead in the U.S. since 2013. In this role, he has built out the organization’s innovation capacity and is responsible for leading innovation capability building and annual programming. He has trained more than 300 innovation champions and leaders and led more than 100 innovation projects over the years, from incremental to disruptive innovation.

Joe has also developed and scaled AbbVie’s Digital Lab with a focus on implementation, strategic roadmap development and innovation and agility training. In addition, Joe developed, launched and activated multiple diversity and inclusion programs with executive teams and frontline commercial leaders.

Prior to his time at AbbVie, Joe held sales, marketing and engineering roles at Abbott before becoming their commercial innovation director in 2007.

Joe has a bachelor’s in chemical engineering from the University of Illinois Chicago and an MBA in marketing from Loyola University Chicago. He is an avid Chicago sports fan and currently resides in Lake County.

Elaine H. Morrato, DrPH FISPE, is professor and founding dean of the Parkinson School of Health Sciences and Public Health at Loyola University Chicago. Trained in epidemiology and board-certified in public health, her scientific contribution focuses on accelerating the translation of health evidence into practice with a particular focus on pharmaceuticals. Earlier in her career, she was a product development manager at Procter and Gamble, where she led multi-functional teams to develop and commercialize prescription and over-the-counter medicines and indications in North America and Europe. This real-world experience informs her academic scholarship and public health practice.

Morrato remains active in research funded by the National Institutes of Health. She directs Loyola’s collaboration with the University of Chicago-Rush University Institute for Translational Medicine and was instrumental in adapting the National Science Foundation’s Innovation-Corps (I-Corps™) training program for clinical and translational science application. Morrato has advised the U.S. Food and Drug Administration (FDA) on issues of pharmaceutical risk management and completed a visiting professorship with the Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research. Her contributions have informed FDA guidance to industry and good pharmacovigilance practice for the European Medicines Agency.

Morrato earned her BS (Honors) summa cum laude from Purdue University, her DrPH and MPH from Johns Hopkins University’s Bloomberg School of Public Health. She is an inducted Fellow in the International Society of Pharmacoepidemiology and in the Institute of Medicine of Chicago. She also received an Executive Certificate from the Kellogg School of Management at Northwestern University.

Michael is a seasoned strategy professional with a passion for advancing healthcare. He has focused his career in life sciences spanning startups, management consulting, pharma, and currently is the head of the Astellas U.S. corporate strategy and innovation team. As part of his current role at Astellas, he is interested in leveraging technology and digital health to improve outcomes, lower costs and ultimately deliver more value in healthcare. Astellas’ Digital Health Incubator also resides within his team, which is designed to enable the adoption of technology across the business.

Michael Tutty, PhD, MHA, FACMPE, is the group vice president leading the strategic focus area of professional satisfaction and practice sustainability at the American Medical Association (AMA). Michael manages AMA’s efforts to identify, support and grow the care delivery and payment models that promote long-term sustainability and satisfaction with medical practice. Before joining the AMA, Michael had several roles at the University of Massachusetts Medical School (UMMS), most recently serving as the director of the office of health policy and technology. Previously, Michael worked at the Boston Consulting Group in their healthcare practice. Michael maintains an assistant professor faculty appointment in the department of family medicine and community health at UMMS. Michael is a board member of Emergence Healthcare Group and Northwest Community Healthcare. He is a fellow of the American College of Medical Practice Executives. Michael earned his bachelor’s in government from Western New England College, his master’s of health administration from Clark University and his doctorate in public policy from the University of Massachusetts Boston.

Nicole Walker is vice president of customer experience at Health Care Service Corporation (HCSC). In her role, she leads a talented, multi-disciplinary customer experience organization that collaborates with partners across the Enterprise to help inform, design and drive a focus on optimizing the stakeholder experience across all HCSC products.

In her former role as senior director, innovation incubator and design leader, she led teams that explore new ideas that re-imagine the health care experience for HCSC stakeholders through HCSC’s Health Innovation Platform (HIP) incubator and accelerator platforms.She also is responsible fora team of talented designers that help re-imagine the user experience for HCSC’s internal and external facing digital assets. Nicole has held successive leadership roles in the sales operations, marketing and strategy, bringing her keen business perspective, strategic thinking and focus on delivering value.

Nicole also is an Adjunct Faculty member of the Inter Professional Program at the Illinois Institute of Technology where she teaches practical applications of human-centered design to undergraduate students via a project-based learning course.

Nicole received her bachelor’s degree in industrial and operations engineering and master’s degree in health services administration from the University of Michigan.She lives in Chicago, with her husband and two children.

Jim is currently the health sciences and wellness market leader for the Americas Central Region of EY. In this role, he leads a team of professionals responsible for delivering exceptional client service in our healthcare and life sciences space. Client organizations include health plans, healthcare providers, medtech and biophrama companies and contract research organizations with headquarters or significant operations in the central and southeast U.S.

In addition, Jim serves on EY’s global health sciences and wellness executive committee as the EY Global Medtech Leader. He co-authors their Pulse of the Industry report and connects teams serving the medical technology industry globally. He is a frequent keynote speaker at industry events and is often quoted in industry publications.

Jim also serves as the global client service partner for a global Medtech company. In this capacity, he is responsible for all the services that EY provides to its business units, regions and functional areas globally. Delivered either in the Americas or coordinated with our global teams, these engagements include EY competencies from our advisory, tax, transactions and assurance practices.

In each of his roles, Jim works to stay aligned to his personal purpose of delivering insight and experiences that increase the accessibility, affordability and innovation of healthcare and educational outcomes.

James joined Evernorth (then Cigna) in 2013 as the organization’s first in-house user-centered designer. In this role, he leads a range of discovery programs specifically crafted to help the organization gain a deeper understanding of stakeholders and consumers in the complex ecosystem of healthcare. He facilitates the translation of knowledge into powerful insights that lead to new solutions and growth strategies by leveraging his strength and experience in user-centered design thinking.

Currently, James is on an international assignment to leverage his expertise in human-centered design and innovation to support the growth of the newly formed Belgian-based international innovation team. With a particular focus on developing a culture of innovation in the international markets business, he is building out emerging capabilities and better integrating innovation practices across the entire global enterprise. To that end, James is incorporating established human-centered design methods and tools, particularly around ideation, prototyping and early-stage concept development to spark front-end innovation. Extending design thinking and innovation training and development in collaboration with the U.S.based Innovation COE, he continues to build strategic connections throughout the organization as well as externally with startups, partners and vendors.

The intersection of technology and healthcare has been Craig’s focus across his career as the director of innovation of BayCare, co-founder of a virtual reality software company in the neuroscience and concussion sectors and during his time with Accenture.

As the director of innovation, Craig builds BayCare’s innovation practice and pursues opportunities to integrate unique, advanced technology-enabled solutions to better serve customers and physicians. Since joining BayCare, he has launched projects including artificial intelligence, an Uber partnership, voice-based technologies for patients, patient-generated health data analytics, clinical communications, wearables, the BayCare TechDeck, collaborations with Apple, Amazon and Fitbit, virtual reality technologies, robotic-enabled virtual experiences for kids and the design of technologies to serve the wellness center of the future.

Daniel Derman, MD has been a practicing internal medicine physician since 1988. He trained at the University of Michigan for his undergraduate studies and went to medical school at the University of Illinois, where he graduated in 1984. He trained in internal medicine from 1984 to 1987 at Northwestern Memorial Hospital and was selected among 35 of his peers to be Chief Medical Resident.

In 1995, Dr. Derman sold his own practice to Northwestern Memorial Healthcare, where it has served as the foundation for Northwestern Medical Group (NMG) — a multispecialty medical group of more than 1,200 physicians. At NMG, he boldly initiated programs such as The Osher Center for Integrative Medicine (one of five selected nationally, and the recipient of a $5 million endowment), a corporate health and wellness program and a community care clinic that provides care to underserved communities — each distinctly unique within an academic medical group setting.

Dr. Derman was appointed as president of Northwestern Memorial Physicians Group and remained in this position throughout 2015. Since that time, he has served as a senior vice president and Chief Innovation Executive of Northwestern Medicine. In addition to his clinical responsibilities and innovation work, he leads the international division and executive health program. Dr. Derman also serves as an advisor for many medical companies and currently sits on the board of Sterilis Medical, a medical waste technology company.

Dr. Derman is a member of the Healthcare Executive Learning Network (a national healthcare think-tank), where he meets three times a year with 25 other top healthcare executives from the United States. He is also a member of AOA, the medical honors society. He has led a volunteer initiative promoting Northwestern employees providing a full day of community service across the Chicagoland area.

Karl Kochendorfer, MD, FAAFP is the Assistant Vice Chancellor for Health Affairs, Chief Health Information Officer and Associate Chief Medical Officer of the University of Illinois Hospital & Health Sciences System (UI Health). He is also an associate professor of clinical family medicine at the University of Illinois at Chicago. He is board certified in clinical informatics and family medicine and has a degree in computer science from the University of Illinois at Urbana-Champaign.

Dr. Kochendorfer is currently a practicing family physician who delivers babies and cares for hospitalized patients at UI Health. He has founded and led many enterprise initiatives, including meaningful use, electronic medical records, clinical documentation improvement, clinical guidelines and protocol oversight, clinical decision support, patient portal and data governance. He also holds several informatics related patents and founded a company and the Collaborative for Health Informatics.

With his background in both medicine and informatics, Dr. Kochendorfer manages the deployment and evaluation of leading-edge solutions to improve efficiency, quality and technology adoption.

Dr. Marcelo Malakooti, MD is medical director of the Lefkofsky Pediatric Intensive Care Unit, where he also serves as a director of innovation and strategy. He is also an assistant professor of pediatrics-critical care at Northwestern University’s Feinberg School of Medicine.

Dr. Malakooti founded IGNITE Innovation, a company that solves challenges using multi-disciplinary cross-pollination for novel interventions, including technology and operational streamlining ranging from improving healthcare quality and patient outcomes, to fostering dynamic strategies to minimize waste and optimize resources. He is also the director of NUvention Medical Innovation for Feinberg School of Medicine, an innovation and entrepreneurship curriculum for multi-disciplinary medical and graduate students, and recently developed the first widely available innovation and entrepreneurial night program for medical students in collaboration with MATTER and the American Medical Association.

Dr. Malakooti received his bachelor’s degree in business administration from George Washington University and his medical degree from Drexel University College of Medicine. He completed his residency at Northwestern University’s Feinberg School of Medicine followed by a fellowship in pediatric critical care medicine. In November of 2015, Dr. Malakooti was named one of Crain’s 40 under 40 proven leaders in their field.

Sharon Markman spent over twenty years at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University building clinical, educational and research programs to support the changing oncology landscape locally and nationally. In 2016, Sharon joined UChicago Medicine to develop the Center for Healthcare Delivery Science and Innovation (HDSI), a matrix center embedded in hospital operations. HDSI focuses on the overlap of health system operations, education, research and innovation. The Center supports “out-of-the-box” thinking to address operational challenges in healthcare. HDSI has provided over $500,000 in research funding to support innovation, partnered with Institute of Design to introduce human centered design and collaborated with many startups from around the world to address access to data and reduce inequity of care to the Southside Chicago community.

Sharon has a MHA from Washington University of St Louis and a BS in Business Administration from the University of Denver. She completed an administrative fellowship at Jewish Hospital (now Barnes-Jewish).

Kristen Murtos is the Chief Innovation & Transformation Officer for Endeavor Health and is responsible for driving innovation and growth to enable peak organizational performance and sustainable differentiation through systematic business and care transformation.

Kristen leads teams and partners with leaders to develop forward thinking solutions for business challenges, inspiring ideas that drive progress, differentiation and future models of care. The innovation strategy combines technology, research, new venture strategies and operations to adapt to dynamic market forces and deliver community-connected care. She leads Innovation, Transformation and has oversight for Health Information Technology and the NorthShore Foundation. Murtos is steadfast in her commitment to bring new insights and capabilities to the front line and deepen consumer understanding to improve care and advance outcomes.

Kristen joined Endeavor Health in 1998 and most recently served as Chief Administrative and Strategy Officer overseeing Strategy, Business Development, Supply Chain, Revenue Cycle, Managed Care Contracting, Legal, Audit & Compliance, Marketing & Corporate Communications and the NorthShore Foundation.

Kristen previously served as President of NorthShore’s Skokie Hospital, and has extensive health care operations experience. Prior to Endeavor Health she worked at Deloitte Consulting where she advised clients in market strategy and operational improvement.

Kristen holds a bachelor’s degree from the University of Illinois and masters’ degrees in business administration and public policy from the University of Chicago. She currently serves on the Ascension Ventures V Board, Vizient CSO Advisory Network, Northwestern Kellogg Advisory Council, Oliver Wyman Health Innovation Leader Alliance and the Advisory Board for the Kindness Connection.